Acer Therapeutics’ EDSIVO™ (celiprolol) Granted FDA Breakthrough Therapy Designation for Vascular Ehlers-Danlos Syndrome - Yahoo Finance
4/4/2022 12:00:00 AM3 yearsago
by Acer Therapeutics Inc.
by Acer Therapeutics Inc.
Discussions ongoing with FDA through special protocol assessment (SPA) seeking agreement on planned pivotal Phase 3 DiSCOVER trial with initiation planned by...
Discussions ongoing with FDA through special protocol assessment (SPA) seeking agreement on planned pivotal Phase 3 DiSCOVER trial with initiation planned by end of Q2 2022 NEWTON, Mass., April 04, … [+11378 chars]
full article...